Osteocyte control of osteoclastogenesis
CA O'Brien, T Nakashima, H Takayanagi - Bone, 2013 - Elsevier
Multiple lines of evidence support the idea that osteocytes act as mechanosensors in bone
and that they control bone formation, in part, by expressing the Wnt antagonist sclerostin …
and that they control bone formation, in part, by expressing the Wnt antagonist sclerostin …
Osteoimmunology and the influence of pro-inflammatory cytokines on osteoclasts
J Zupan, M Jeras, J Marc - Biochemia medica, 2013 - hrcak.srce.hr
Sažetak Bone and immune system are functionally interconnected. Immune and bone cells
derive from same progenitors in the bone marrow, they share a common microenvironment …
derive from same progenitors in the bone marrow, they share a common microenvironment …
Nrf2 deficiency induces oxidative stress and promotes RANKL-induced osteoclast differentiation
S Hyeon, H Lee, Y Yang, W Jeong - Free Radical Biology and Medicine, 2013 - Elsevier
Nuclear factor-erythroid 2-related factor 2 (Nrf2) is a redox-sensitive transcription factor that
regulates the expression of a variety of antioxidant and detoxification genes through an …
regulates the expression of a variety of antioxidant and detoxification genes through an …
Metabolic regulation of osteoclast differentiation and function
The osteoclast is a giant cell that resorbs calcified matrix by secreting acids and
collagenolytic enzymes. The molecular mechanisms underlying metabolic adaptation to the …
collagenolytic enzymes. The molecular mechanisms underlying metabolic adaptation to the …
Autoinflammatory bone disorders with special focus on chronic recurrent multifocal osteomyelitis (CRMO)
CM Hedrich, SR Hofmann, J Pablik, H Morbach… - Pediatric …, 2013 - Springer
Sterile bone inflammation is the hallmark of autoinflammatory bone disorders, including
chronic nonbacterial osteomyelitis (CNO) with its most severe form chronic recurrent …
chronic nonbacterial osteomyelitis (CNO) with its most severe form chronic recurrent …
Targeting monocytes/macrophages in the treatment of rheumatoid arthritis
JL Davignon, M Hayder, M Baron, JF Boyer… - …, 2013 - academic.oup.com
Biotherapies have revolutionized the treatment of RA. However, much work is needed to
understand all the mechanisms of these biotherapies, and alternatives are needed to …
understand all the mechanisms of these biotherapies, and alternatives are needed to …
A RANKL–PKCβ–TFEB signaling cascade is necessary for lysosomal biogenesis in osteoclasts
Bone resorption by osteoclasts requires a large number of lysosomes that release proteases
in the resorption lacuna. Whether lysosomal biogenesis is a consequence of the action of …
in the resorption lacuna. Whether lysosomal biogenesis is a consequence of the action of …
Advances in osteoclast biology reveal potential new drug targets and new roles for osteoclasts
BF Boyce - Journal of Bone and Mineral Research, 2013 - academic.oup.com
Osteoclasts are multinucleated myeloid lineage cells formed in response to macrophage
colony‐stimulating factor (M‐CSF) and receptor activator of NF‐κB ligand (RANKL) by fusion …
colony‐stimulating factor (M‐CSF) and receptor activator of NF‐κB ligand (RANKL) by fusion …
miR-31 controls osteoclast formation and bone resorption by targeting RhoA
F Mizoguchi, Y Murakami, T Saito, N Miyasaka… - Arthritis research & …, 2013 - Springer
Introduction Increased activity of osteoclasts is responsible for bone loss and joint
destruction in rheumatoid arthritis. For osteoclast development and bone resorption activity …
destruction in rheumatoid arthritis. For osteoclast development and bone resorption activity …
Osteoclast migration, differentiation and function: novel therapeutic targets for rheumatic diseases
J Kikuta, M Ishii - Rheumatology, 2013 - academic.oup.com
RA is a chronic autoimmune disease characterized by joint synovial inflammation and
progressive cartilage/bone destruction. Although various kinds of RA drug have been …
progressive cartilage/bone destruction. Although various kinds of RA drug have been …